生物技术药物发展现状及我国的对策研究

生物技术药物产业是近些年来新兴的高端产业,生物技术药物产业的发展与国计民生息息相关,具有广阔的发展前景和进步空间。本文主要就生物技术药物发展的现状进行分析,提出具体的对策,促进我国生物技术药物的快速发展。

Advances in Plant Science and Its Prospects

Focusing on the global food security and analyzing the challenges now confronting human being of global climate change,sustainable development of agriculture,energy and environment,plant scientists should take the social responsibility and play the role in solving the global problems like food security from the developmental status and potential of plant science and technology. Moreover,by working with agronomists, ecologists and environmental experts,plant scientists do provide novel ideas and technologies for developing low carbon agriculture,for breeding new crop varieties with high yield and quality and stress resistance,for developing new type of energy plants,for supplying healthy foods and drugs,reasonably using land and water resources,and for ameliorating environment,making better contribution to the sustainable development of the globe and human being ourselves.

Erythropoietin： From a Biosimilar to Innovative Products Protected by Industrial Property Assets

Aim： EPO （erythropoietin） is a hormone that stimulates the erythropoiesis and is mainly produced by the kidneys. In the early 1990s among the emerging biotech drugs, the recombinant human EPO （rhEPO） was the best-selling product worldwide, reaching nearly three billion dollars annually. The CIM （center of molecular immunology） produced and sold the rhEPO as commercial strategy to recover the investment made in its new facilities. This work summarizes the inventions that protect the innovative products developed by three Cuban institutions, starting from rhEPO, and the industrial property strategy followed by them. Methods： The information was obtained from the United States Patent, Trademark Office （USPTO） database, Patentscope, Espacenet, patent databases of Center for Pharmaceutical Research and Drug Development （CIDEM） and Cuban Industrial Property Office. Conclusions： The manufacturing process of CIM＇s EPO has its own patent family. From a manufacturing by product an innovative formulation protected by patent was obtained. There is a patent family around the nasal formulation and it continues enlarging. From a biosimilar pharmaceutical innovative products impacting on human health have been obtained.

Medicinal Solid Fermentation Engineering of Chinese Traditional Medicinal Fungal

Medicinal solid fermentation technology of fungal was unique within the traditional Chinese medicine （TCM） and one of the oldest bio-pharmaceutical technology in the history, for example, the production of medicated leaven named ＂Shenqu＂, the history of which had continued for more than 1,500 years. These kinds of productions were widly used and had a close relationship with TCM. The development of this technology had through stages of ＂yeast production＂, ＂solid culture＂, ＂solid fermentation＂, and nowadays toward a series engineering of solid fermentation with promising prospects. The author described the development of its history briefly, and the representative products and the characteristics of production process of every stage, respectively. This research focused on taking ＂Trametes robinioplila fermented substance＂, ＂T. robinioplila ＆ A. membranaceus fermented substance＂ and ＂T. wilfordii Hook.f. ＆ G. lucidum fermented substance＂ as examples to introduce R ＆ D ideas and important findings of＂common fermentation＂ and ＂bi-directional fermentation＂ which were recommended as studying hotspots. There were many unique and important functions in the fields of TCM about all kinds of＂fermentation substances＂. It is infered that there may exist some other innovate technologies such as ＂Multi-fungal fermentation＂, ＂Special elements fermentation＂, etc. which are remained to be researched and developed continuely. All kinds of＂fermentation substances＂ are looked forward to show unique and important roles in the fields of TCM.

Developing an Efficient Technology for Key Intermediates Production Used in Enzymatic Synthesis of Cladribine and Nelarabine

The pilot-scale process for preparing 2-amino-6-chloro-9-（2＇,3＇,5＇-tri-O-acetyl-Dq3-ribofuranosyl）-purine and 2-chloroadenosine has been developed with a total yield of the desired compounds 73% and 44.5%, respectively. These compounds are useful intermediates for enzymatic synthesis of active pharmaceutical ingredients Nelarabine and Cladribine. The starting material--commercially avaliable guanosine--was acetylated with acetic anhydride, yielding 2,3,5-tri-O-acetylguanosine, which was further deoxyhalogenated with phosphorous oxychloride in presence of tetraethylammonia chloride. Diazotization of the resulting intermediate with tert-butylnitrite leads to the corresponding ribofuranosyl-substituted 2,6-dichloropurine, which was converted to 6-chloroadenosine by reaction with methanolic ammonia.

Application of Systems Biology Technology in Research of Traditional Chinese Medicine

Systems biology is an emerging science of the 21st century and its method and design of study resemble those of traditional Chinese medicine (TCM). Adopting systems biology technology will help to understand TCM Syndromes and modernize Chinese herbal medicine. The technology platforms of systems biology, especially proteomics can provide useful tools for exploring essence of TCM syndromes and understanding principle of herbal formulation. Moreover, compared with methods of molecular biology, such as genomics and proteomics, metabolomics provide more direct, rapid, concise and effective methods for study of kidney disease especially in the case of prevention and treatment with TCM.